Research on Alzheimer's disease, from early signs to new therapies. Covers screening tools, brain damage mechanisms, risk factors, sleep, and drug targets.
A large-scale study found that having multiple heart-related conditions significantly increases dementia risk, even for those with high genetic risk. Researchers analyzed data from over 200,000 people and discovered widespread brain damage among those with more than one cardiometabolic condition.
Researchers will track changes in the blood-brain barrier, neurovascular function, and cognition in over 850 participants with genetic variants at risk of developing Alzheimer’s disease. The study aims to improve understanding of the onset and progression of Alzheimer’s disease and identify effective interventions.
Researchers at UT Health San Antonio found that rapamycin causes an increase in beta-amyloid protein plaques in mouse models, contradicting its potential benefits. However, a novel method to decrease plaques was discovered by deleting the Tsc1 gene from microglia, leading to increased Trem2 levels and decreased plaques.
A new study shows that hospice patients with dementia receive excellent care and have their anxiety and sadness managed more often than those without dementia. However, the Medicare hospice model's limitations can lead to gaps in care, leaving patients with dementia at risk of disenrollment.
Researchers at Karolinska Institutet found a link between genetic variants in diabetes drug targets and lower Alzheimer's disease risk. The study suggests that the target protein, KATP channel, may be a therapeutic target for treating and preventing Alzheimer's disease.
Researchers found that neuronal damage in Alzheimer's disease originates from within brain cells' lysosomes, where amyloid beta appears. This discovery could explain why drugs designed to remove amyloid deposits have failed to stop the disease.
A recent study at UC San Francisco discovered that fragmented tau protein in diseased neurons could be a new target for existing drugs, potentially improving diagnosis and treatment of Alzheimer's. The researchers found that measuring the fragments in cerebrospinal fluid may help distinguish between different forms of dementia.
Researchers are assessing cognitive decline in aging Latinos, exploring the long-term impact of COVID-19 and cardiovascular disease on brain function and impairment. The study will gather data to develop real-world therapies and potentially lessen the disease burden of dementia affecting Latinos.
Researchers at Cedars-Sinai have comprehensively mapped molecular activity in the brain and spinal cord that regulates body's response to central nervous system (CNS) disorders. They discovered a critical role of astrocytes, specialized support cells, in regulating outcomes for CNS disorders.
A study conducted by Kaunas University of Technology researchers analyzed how people with Alzheimer's disease process visual information from faces. The study found that brain signals in patients are significantly noisier, making it harder for them to focus and be attentive.
A new study from Michigan Medicine reveals that dementia diagnoses are often accompanied by significant increases in healthcare costs. The research found that the average Medicare spending jumped by 150% after a formal diagnosis of Alzheimer's disease or another type of dementia.
Researchers at Indiana University School of Medicine have made significant progress in developing blood tests for Alzheimer's diagnosis and treatment. The latest study, published in Nature Medicine, explores the utility of phosphorylated tau (P-tau) blood biomarkers to aid in early detection and improve disease management.
Researchers at the University of Warwick have identified a novel cellular process called Golgiphagy that helps regulate the degradation of the Golgi complex in cells. This discovery opens new avenues for understanding the underlying mechanisms of diseases such as cancer, Alzheimer's, and Parkinson's.
Alzheimer's disease causes cells to overheat due to amyloid-beta aggregation, which can lead to more aggregates forming. The researchers found a drug compound could stop this process, potentially leading to new treatments.
Researchers found promising new biomarkers for Alzheimer's disease in blood tests, but found that comorbidities can increase levels and provide false positive results. The study suggests more research is needed before these tests can be used in clinical settings.
Researchers at UCLA have discovered a key molecular mechanism behind memory linking and identified an FDA-approved drug that can restore this brain function in middle-aged mice. The study suggests a potential early intervention for dementia and strengthening human memory in middle age.
A study by Columbia University researchers found that the gene FMNL2 links cerebrovascular disease and Alzheimer's disease, suggesting changes in FMNL2 activity cause toxic protein clearance issues. This mechanism may lead to a way to prevent Alzheimer's in people with hypertension, diabetes, or heart disease.
Researchers discovered a specific glycoprotein, RPTP zeta S3L, that connects to CD33 receptors in the brain, limiting its ability to clean up harmful proteins. This finding may lead to new drug targets and early diagnostics for Alzheimer's disease.
Researchers at West Virginia University are studying the mechanisms behind Alzheimer's disease and PTSD, using animal models to investigate how stressful events affect brain cells. They aim to understand the role of estrogen and high-cholesterol diet in developing the disease.
Researchers found that rifampicin improved cognitive function and memory in mice with C9orf72-linked dementia. The antibiotic also reduced formation of protein aggregates, neuronal loss, and microglial activation in brain tissue. This study suggests rifampicin may be a widely effective drug for preventing neurodegenerative diseases.
A novel preclinical drug has been developed to inhibit the kinase enzyme Cdk5, which is implicated in neuropsychiatric and neurodegenerative conditions. The drug, 25-106, is brain-permeable and shows promise in altering neurobehavior in mice with anxiety-like behavior.
Researchers at Marshall University Joan C. Edwards School of Medicine are studying the role of obesity and oxidative stress in Alzheimer's disease. Obesity is a key predictive factor for Alzheimer's disease, which affects 14 million Americans by 2060.
Researchers found signs of concussions and head trauma in the brains of deceased headbutting muskoxen and bighorn sheep. The study provides insights into human injuries and opens the possibility that studying these animals could help researchers understand and reduce traumatic brain injuries.
A new study found a link between increased choroid plexus volume and greater cognitive impairment in Alzheimer's disease. Choroid plexus volume was associated with memory loss, executive function decline, and cognitive impairment severity.
A team of researchers has developed a novel method using infrared imaging to assess glymphatic function, which is crucial for understanding neurological conditions. The technique allows for the measurement of temporal dynamics of glymphatic functions and provides insights into brain fluid exchange and clearance.
Researchers have discovered a new biomarker for blood-brain barrier dysfunction in Alzheimer's disease, associated with the presence of the APOE ε4 allele. The study found that APOE ε4 dose is linked to poor brain-waste clearance through the BBB, causing iron and β-amyloid accumulation.
Researchers aim to develop an audio health library to enhance communication during triadic visits. The study will analyze primary care visits and conduct user-design sessions to refine the system.
Researchers at Universitat Politècnica de València have developed 3D-printed acoustic holograms that can open the blood-brain barrier, allowing for precise administration of therapeutic drugs to treat Alzheimer's and Parkinson's diseases. The technology enables controlled focusing of ultrasonic beams on specific brain structures.
Researchers discovered a strong link between subjective cognitive impairments and elevated beta-amyloid protein levels, indicating early-stage Alzheimer's disease. The study suggests that combining these two factors can help identify individuals at risk for developing dementia.
Researchers suggest a novel neuroimaging technique can unveil Alzheimer's disease secrets and predict symptom risk. The 'neuromelanin-sensitive MRI' method provides insights into the brain's noradrenergic system, linked to aggressive behavior and cognitive decline.
Researchers have found blood proteins that cause migraine, including DKK1 and PDGFB, which inhibit Wnt signalling pathways. Lower levels of antioxidant proteins FARS2, GSTA4, and CHIC2 also contribute to inflammation linked to migraine. Therapies targeting increased DKK1 levels may represent novel tools for treatment.
A University of Cincinnati study found that adding blueberries to middle-aged diets may lower the chances of developing late-life dementia. The researchers discovered that blueberries' high level of micronutrients and antioxidants helped improve cognitive function and metabolic function.
Researchers assessed modifiable risk factors for Alzheimer disease and related dementias in the US population, finding significant differences by sex, race, and ethnicity. The study highlights the importance of addressing these disparities to prevent cognitive decline.
A new study suggests that supplementing a diet with Ascidiacea, also known as sea squirts, reverses some main signs of aging in animal models. The researchers found that plasmalogens, vital to body processes, decrease with age and contribute to neurodegenerative diseases like Alzheimer's and Parkinson's.
Researchers have developed a multi-dimensional approach to quantify cognitive decline in aging dogs, which may also inform human Alzheimer's disease treatment. The method combines physical exams, lab tests, and cognitive assessments to provide a more complete picture of canine cognitive function.
A study analyzing Medicare claims data found that policy changes reduced the share of patients receiving hospice care for Alzheimer's disease and related dementias. The changes also slowed growth in hospice care use by these patients.
Researchers at the University of Cambridge have identified a new mechanism that appears to reverse the build-up of aggregates in neurodegenerative diseases, such as Alzheimer's and Parkinson's. By stressing cells, they found that protein misfolding was eliminated, potentially allowing for the refolding of correctly folded proteins.
A clinical trial found that sodium selenate stabilizes escalating behavioural issues and slows brain shrinkage in patients with behavioural variant frontotemporal dementia. The treatment has been shown to be safe and well-tolerated, with reduced rates of cognitive and behavioural symptoms.
A new study found that half of older adults with both hearing and vision impairment have serious cognitive decline, compared to 28% with only vision impairment. The study highlights the importance of considering sensory impairments in identifying those at risk for cognitive decline.
Researchers at the University of Kansas have discovered a promising new basis for active immunization against Alzheimer's disease. By injecting a recombinant methionine-rich protein into mice with the disease, they were able to improve short-term memory and learning abilities by up to 50%. The treatment also showed potential in reducin...
A new study found a consistent increase in PHGDH expression among Alzheimer's patients and asymptomatic individuals, suggesting increased serine production in the brain. The findings prompt caution against taking serine supplements for Alzheimer's disease treatment or prevention.
Researchers used PET and fMRI to study brain connectivity changes years before symptoms of Alzheimer's disease appear. Disruptions were found in the main memory network, even before cognitive impairment was observed, suggesting potential strategies for early detection.
Researchers at UC San Diego have developed a smartphone app that uses near-infrared camera technology to track pupil size changes, which can indicate cognitive conditions. The app is designed to be user-friendly for older adults and has shown comparable results to traditional pupillometry devices.
A phase 2 randomized controlled clinical trial found that intranasal insulin increased walking speed, cerebral blood flow, and improved decision making and verbal memory. The treatment also showed promise for preventing or slowing the progression of Alzheimer's disease-related dementias in older adults.
Astrocytes, comprising nearly half of all brain cells, have been found to perform an electrically active function that influences neurotransmitter release and brain disease pathology. This discovery opens new avenues for neuroscience research and potential treatments for conditions like Alzheimer's and epilepsy.
Researchers have identified key metabolic drivers of late-onset Alzheimer's disease, providing insights for personalized medicine. The study found that the APOEe4 genotype influences metabolic changes, overriding sex-specific differences in males and females.
Researchers from Indiana University School of Medicine identify a key brain receptor that leads to a loss of neurons and synaptic structure in Alzheimer's disease models. The study found that targeting this receptor could prevent or delay the onset of Alzheimer's-related neuropsychiatric symptoms and cognitive deficits.
A Boston University study found that living in areas with more greenery may boost cognitive function, particularly in middle-aged women. The research suggests that exposure to greenspace could improve processing speed and attention, as well as reduce depression, a risk factor for dementia.
Scientists at Gladstone Institutes have discovered that reducing protein tau levels soon after birth can prevent autism and epilepsy in an experimental model. The study pinpointed the crucial brain cells where tau levels must be reduced to avoid these problems, and showed that lowering tau is still effective when initiated after birth.
A new AI-based method distinguishes between stable and progressive cognitive impairment, enabling accurate diagnosis with an accuracy rate of 85%. This technique overcomes the complexity of subtle structural changes in mild cognitive impairment, contributing to achieving Sustainable Development Goal 3.
Researchers found that people with advanced Alzheimer’s disease and related dementias who live in the community experience similar symptom burdens to those in nursing homes. The study suggests that palliative care interventions could ease symptom burden and improve quality of life for patients and caregivers.
A clinical trial is underway to test the safety and efficacy of PhytoSERM, a dietary supplement that promotes estrogenic action in the brain without affecting reproductive tissue. The study aims to reduce menopausal symptoms and lower the risk of Alzheimer's disease in post- and perimenopausal women.
Researchers at Albert Einstein College of Medicine are awarded a $4.2 million NIH grant to detect behavioral markers for Alzheimer's disease that appear early in the course of the disease. The study aims to identify people at risk and develop new preventive strategies.
A study led by Richard Isaacson found that individualized, multi-domain interventions improved cognition and reduced Alzheimer's risk in both men and women. Women demonstrated greater improvements in certain risk scores and biomarkers compared to men.
Researchers at Michigan State University have made a discovery that could lead to new treatments for Alzheimer's disease. By regulating an intramembrane protease, also known as gamma-secretase, which is implicated in the disease, they found a potential target for therapies.
A new Cochrane Review paper reveals that talk therapy can alleviate depression and improve quality of life for people with dementia. The study found that psychological interventions, such as Cognitive Behavioural Therapy (CBT), are effective in reducing symptoms of depression and improving wellbeing.
Research suggests that EMFs can cause Alzheimer's disease by building up calcium levels in brain cells. This increase leads to changes in the brain, which develop conditions for Alzheimer's. The study highlights the importance of reducing EMF exposure to prevent or delay the onset of Alzheimer's.
Research presents a promising path forward for early identification and intervention of Alzheimer's disease through the study of executive function and biomarkers. A link to genetics research is also being explored to better understand genetic and environmental factors that influence cognitive and brain aging.
A unique ratio of metabolites in blood samples may facilitate faster diagnosis of early-stage Alzheimer's disease. The discovery promises to reduce reliance on amyloid fragments, which can be detected using existing equipment.
A new study published in the Endocrine Society's Journal of Clinical Endocrinology and Metabolism found that people with type 2 diabetes and cognitive impairment have a higher risk of heart attack and stroke. Cognitive function may predict a person's future risk of heart disease, according to researchers.